Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study.
Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, Bechade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Desrame J, Artru P, Thirot Bidault A, Le Roy B, Pezet D, Phelip JM, Taieb J. Williet N, et al. Among authors: le roy b. Therap Adv Gastroenterol. 2019 Sep 25;12:1756284819878660. doi: 10.1177/1756284819878660. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31598136 Free PMC article.
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL, Tougeron D, Pernot S, Pozet A, Béchade D, Trouilloud I, Lourenco N, Hautefeuille V, Locher C, Williet N, Desrame J, Artru P, Soularue E, Le Roy B, Taieb J. Pointet AL, et al. Among authors: le roy b. Clin Res Hepatol Gastroenterol. 2020 Jun;44(3):295-301. doi: 10.1016/j.clinre.2019.08.009. Epub 2019 Oct 10. Clin Res Hepatol Gastroenterol. 2020. PMID: 31607641
How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort.
Pietrasz D, Turrini O, Vendrely V, Simon JM, Hentic O, Coriat R, Portales F, Le Roy B, Taieb J, Regenet N, Goere D, Artru P, Vaillant JC, Huguet F, Laurent C, Sauvanet A, Delpero JR, Bachet JB, Sa Cunha A. Pietrasz D, et al. Among authors: le roy b. Ann Surg Oncol. 2019 Jan;26(1):109-117. doi: 10.1245/s10434-018-6931-6. Epub 2018 Oct 25. Ann Surg Oncol. 2019. PMID: 30362063
Local treatment in the setting of de novo metastatic rectal cancer: reappraisal of prognostic factors.
Vial N, Langrand-Escure J, Diao P, Garcia MA, Jmour O, Ben Mrad M, Guy JB, Abid W, Sotton S, Espenel S, Guillaume E, Rehailia-Blanchard A, Pigné G, Trone JC, Rancoule C, Kaczmarek D, Muron T, Le Roy B, Phelip JM, Vallard A, Magné N. Vial N, et al. Among authors: le roy b. Swiss Med Wkly. 2021 Dec 15;151:w30034. doi: 10.4414/smw.2021.w30034. eCollection 2021 Dec 6. Swiss Med Wkly. 2021. PMID: 34964579 Free article.
BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
Bachet JB, Moreno-Lopez N, Vigano L, Marchese U, Gelli M, Raoux L, Truant S, Laurent C, Herrero A, Le Roy B, Deguelte Lardiere S, Passot G, Hautefeuille V, De La Fouchardiere C, Artru P, Ameto T, Mabrut JY, Schwarz L, Rousseau B, Lepère C, Coriat R, Brouquet A, Sa Cunha A, Benoist S. Bachet JB, et al. Among authors: le roy b. Br J Surg. 2019 Aug;106(9):1237-1247. doi: 10.1002/bjs.11180. Epub 2019 Jun 10. Br J Surg. 2019. PMID: 31183866
277 results